Back to Search Start Over

Factors Associated With an Electronic Health Record-Based Definition of Postacute Sequelae of COVID-19 in Patients With Systemic Autoimmune Rheumatic Disease.

Authors :
Patel NJ
Wang X
Lin M
Kowalski EN
Cook CE
Vanni KMM
Guzzo K
Qian G
Bade KJ
Saavedra A
Venkat R
Srivatsan S
Williams ZK
Hanberg JS
Kawano Y
Schiff AE
Sparks JA
Wallace ZS
Source :
The Journal of rheumatology [J Rheumatol] 2024 May 01; Vol. 51 (5), pp. 529-537. Date of Electronic Publication: 2024 May 01.
Publication Year :
2024

Abstract

Objective: Many individuals with rheumatic disease are at higher risk for severe acute coronavirus disease 2019 (COVID-19). We aimed to evaluate risk factors for postacute sequelae of COVID-19 (PASC) using an electronic health record (EHR)-based definition.<br />Methods: We identified patients with prevalent rheumatic diseases and COVID-19 within the Mass General Brigham healthcare system. PASC was defined by the International Classification of Diseases, 10th revision (ICD-10) codes, relevant labs, vital signs, and medications at least 30 days following the first COVID-19 infection. Patients were followed until the earliest of incident PASC, repeat COVID-19 infection, 1 year of follow-up, death, or February 19, 2023. We used multivariable Cox regression to estimate the association of baseline characteristics with PASC risk.<br />Results: Among 2459 patients (76.37% female, mean age 57.4 years), the most common incident PASC manifestations were cough (14.56%), dyspnea (12.36%), constipation (11.39%), and fatigue (10.70%). Serious manifestations including acute coronary disease (4.43%), thromboembolism (3.09%), hypoxemia (3.09%), stroke (1.75%), and myocarditis (0.12%) were rare. The Delta wave (adjusted hazard ratio [aHR] 0.63, 95% CI 0.49-0.82) and Omicron era (aHR 0.50, 95% CI 0.41-0.62) were associated with lower risk of PASC than the early pandemic period (March 2020-June 2021). Age, obesity, comorbidity burden, race, and hospitalization for acute COVID-19 infection were associated with greater risk of PASC. Glucocorticoid (GC) use (aHR 1.19, 95% CI 1.05-1.34 compared to no use) was associated with greater risk of PASC.<br />Conclusion: Among patients with rheumatic diseases, following their first COVID-19 infection, we found a decreased risk of PASC over calendar time using an EHR-based definition. Aside from GCs, no specific immunomodulatory medications were associated with increased risk, and risk factors were otherwise similar to those seen in the general population.<br /> (Copyright © 2024 by the Journal of Rheumatology.)

Details

Language :
English
ISSN :
1499-2752
Volume :
51
Issue :
5
Database :
MEDLINE
Journal :
The Journal of rheumatology
Publication Type :
Academic Journal
Accession number :
38428964
Full Text :
https://doi.org/10.3899/jrheum.2023-1092